Insider · CIK 0002069239
Janeen Noel Doyle
Files at JANX (Janux Therapeutics, Inc.). First filing Jun 4, 2026, latest Jun 4, 2026.
Janeen Noel Doyle files SEC Form 4 as officer at JANX (Janux Therapeutics, Inc.). Since Jun 4, 2026, Janeen Noel Doyle has reported 0 open-market buys worth $0 and 1 open-market sell worth $57k, the latest filed on Jun 4, 2026.
A track record needs three past buys with six months of prices behind them; Janeen Noel Doyle has 0, so none is measured yet.
The newest scored trade: sold $57k of JANX on Jun 2, 2026, filed Jun 4, 2026, scored 22 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $57k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JANX: Janux Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | JANXsell Janux Therapeutics, Inc. | $57k 4,059 shares | -5% | +13% from low-60% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -4,059 | $14.03 | $57k | 75,941 | Jun 4, 2026 |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +36,000 | $0.00 | $0 | 80,000 | Jan 2, 2026 |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +126,000 | $0.00 | $0 | 126,000 | Jan 2, 2026 |
| Jun 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 44,000 | Jun 4, 2025 |
| Jun 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +154,000 | $0.00 | $0 | 154,000 | Jun 4, 2025 |
Questions about Janeen Noel Doyle
Answered from the filings on this page, as of the latest one.
Is Janeen Noel Doyle buying or selling?
In the last 12 months Janeen Noel Doyle reported 0 open-market buys worth $0 and 1 open-market sell worth $57k on SEC Form 4; the latest was sold $57k of JANX on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Janeen Noel Doyle's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Janeen Noel Doyle has 0.
Where does Janeen Noel Doyle file Form 4?
Janeen Noel Doyle has filed Form 4 at JANX (Janux Therapeutics, Inc.) as Chief Corp. & Bus. Dev. Ofcr. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.